Medizinische Klinik

, Volume 105, Issue 3, pp 163–175 | Cite as

GLP-1: ein neues Therapieprinzip für die Behandlung des Diabetes mellitus Typ 2

  • Björn A. Menge
  • Juris J. Meier
  • Wolfgang E. Schmidt
Praxis-Fortbildung Innere Medizin
First Online:
  • 79 Downloads

Kasuistik

Bei einem 58-jährigen Patienten, der aufgrund einer Psoriasis in der dermatologischen Abteilung einer Universitätsklinik behandelt wird, zeigt sich in der Labordiagnostik ein HbA1c-Wert von 8,4%. Die Laborkontrolle wurde durchgeführt, da bei dem Patienten vor 3 Jahren ein Diabetes mellitus Typ 2 festgestellt worden war. Der Patient hat einen Body-Mass-Index von 29 kg/m2, und es sind eine arterielle Hypertonie und Dyslipoproteinämie bekannt. In den Blutzuckertagesprofilen fallen insbesondere erhöhte postprandiale Blutzuckerspiegel mit Werten von 230 mg/dl auf. Bereits bei der Erstdiagnose ist eine Behandlung mit Metformin eingeleitet worden, die aktuelle Dosierung liegt bei 2 x 1000 mg. Durch die diabetologische Abteilung der Klinik erfolgt die Einleitung einer Add-on-Therapie mit Sitagliptin (JANUVIA®) 100 mg/Tag. Darunter kommt es im Laufe von 10 Tagen zu einer Normalisierung der erhöhten Blutzuckerspiegel, und der HbA1c-Wert liegt nach 3 Monaten bei 6,7%.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Icks A, Rathmann W, Haastert B, et al. [Quality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000.] Dtsch Med Wochenschr 2006;131:73–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75–85.CrossRefPubMedGoogle Scholar
  4. 4.
    Dupre J, Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973;37:826–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985;28:704–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239–46.CrossRefPubMedGoogle Scholar
  8. 8.
    Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Lu M, Wheeler MB, Leng XH, et al. Stimulation of insulin secretion and insulin gene expression by gastric inhibitory polypeptide. Trans Assoc Am Physicians 1993;106:42–53.PubMedGoogle Scholar
  11. 11.
    Ritzel R, Orskov C, Holst JJ, et al. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 1995;38:720–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53:654–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Nauck MA, Bartels E, Orskov C, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Meier JJ, Hucking K, Holst JJ, et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001;50:2497–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004;53:Suppl 3:S220–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Meier JJ, Nauck MA, Siepmann N, et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003;52:1579–85.CrossRefPubMedGoogle Scholar
  18. 18.
    Nauck MA, El-Ouaghlidi A, Gabrys B, et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004;122:209–17.CrossRefPubMedGoogle Scholar
  19. 19.
    Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Ritzel RA, Butler AE, Rizza RA, et al. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 2006;29:717–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628–35.CrossRefPubMedGoogle Scholar
  23. 23.
    DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–100.CrossRefPubMedGoogle Scholar
  24. 24.
    Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47.CrossRefPubMedGoogle Scholar
  26. 26.
    Nauck MA, Ratner RE, Kapitza C, et al. Treatment with the human once-weekly glucagon-like peptide- 1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009;32:1237–43.CrossRefPubMedGoogle Scholar
  27. 27.
    Matthews JE, Stewart MW, De Boever EJ, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487–93.CrossRefPubMedGoogle Scholar
  29. 29.
    Mentlein R. Dipeptidyl-peptidase IV (CD26) — role in the inactivation of regulatory peptides. Regul Pept 1999;85:9–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217–23.CrossRefPubMedGoogle Scholar
  32. 32.
    Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733–45.CrossRefPubMedGoogle Scholar
  34. 34.
    Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148–55.CrossRefPubMedGoogle Scholar
  35. 35.
    Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175–85.CrossRefPubMedGoogle Scholar
  36. 36.
    DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649–55.CrossRefPubMedGoogle Scholar
  37. 37.
    Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395–406.CrossRefPubMedGoogle Scholar
  38. 38.
    Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46–52.CrossRefPubMedGoogle Scholar
  40. 40.
    Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 2003;17:93–102.CrossRefPubMedGoogle Scholar

Copyright information

© Urban & Vogel, Muenchen 2010

Authors and Affiliations

  • Björn A. Menge
    • 1
    • 2
  • Juris J. Meier
    • 1
  • Wolfgang E. Schmidt
    • 1
  1. 1.Medizinische Klinik I, St. Josef-HospitalUniversitätsklinikum der Ruhr-Universität BochumBochumGermany
  2. 2.Medizinische Klinik I, St. Josef-HospitalUniversitätsklinikum der Ruhr-Universität BochumBochumGermany

Personalised recommendations